Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Leitzel

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Cancer Research|February 18, 2011
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimersRitwik Ghosh, Archana Narasanna, Shizhen Emily Wang, et al.
Cancer|September 10, 2020
Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trialPrashanth Moku, Lois Shepherd, Suhail M Ali, et al.
Breast Cancer Research and Treatment|August 21, 2013
HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancerAllan Lipton, Laurie Goodman, Kim Leitzel, et al.
Cellular and Molecular Life Sciences : CMLS|March 25, 2022
Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor typesNicholas Willumsen, Christina Jensen, George Green, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Cancer Research|February 18, 2011
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimersRitwik Ghosh, Archana Narasanna, Shizhen Emily Wang, et al.
Cancer|September 10, 2020
Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trialPrashanth Moku, Lois Shepherd, Suhail M Ali, et al.
Breast Cancer Research and Treatment|August 21, 2013
HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancerAllan Lipton, Laurie Goodman, Kim Leitzel, et al.
Cellular and Molecular Life Sciences : CMLS|March 25, 2022
Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor typesNicholas Willumsen, Christina Jensen, George Green, et al.
Pageof 4